CN110664997A - Preparation method and application of chicken coccidiosis trivalent live vaccine - Google Patents

Preparation method and application of chicken coccidiosis trivalent live vaccine Download PDF

Info

Publication number
CN110664997A
CN110664997A CN201910941406.2A CN201910941406A CN110664997A CN 110664997 A CN110664997 A CN 110664997A CN 201910941406 A CN201910941406 A CN 201910941406A CN 110664997 A CN110664997 A CN 110664997A
Authority
CN
China
Prior art keywords
eimeria
live vaccine
chicken coccidiosis
coccidiosis
chicken
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201910941406.2A
Other languages
Chinese (zh)
Inventor
陈庆忠
安同伟
李迎梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Heelion Te Biological Science And Technology Co Ltd
Original Assignee
Tianjin Heelion Te Biological Science And Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Heelion Te Biological Science And Technology Co Ltd filed Critical Tianjin Heelion Te Biological Science And Technology Co Ltd
Priority to CN201910941406.2A priority Critical patent/CN110664997A/en
Publication of CN110664997A publication Critical patent/CN110664997A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/012Coccidia antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to a preparation method and application of a chicken coccidiosis trivalent live vaccine, wherein the vaccine is prepared by uniformly mixing three kinds of early-maturing breeding attenuated insect strains of Eimeria tenella, Eimeria necatrix and Eimeria maxima and storing the mixture in a storage solution; the invention also relates to a preparation method and application of the chicken coccidiosis trivalent live vaccine, which adopts physical weakening, has no drug residue and drug resistance, has good immunogenicity, is safe and has no stress, and can be used for preventing chicken coccidiosis in large-scale farms.

Description

Preparation method and application of chicken coccidiosis trivalent live vaccine
Technical Field
The invention belongs to the field of biological products for livestock, and particularly relates to a preparation method and application of a chicken coccidiosis trivalent live vaccine.
Background
Coccidiosis, a common disease that endangers the poultry industry, causes economic losses of $ 30 billion globally each year, which is characterized in that one or more Eimeria parasites on epithelial cells of chicken intestinal tracts to infect the damaged epithelial of chicken intestinal tracts and mucous membranes of chicken, the death rate is up to 80 percent due to poor digestion and absorption of the intestinal tracts and even death, and at present, the Eimeria parasites are mainly prevented by anticoccidial drugs and virulent coccidian seedlings, but with the increasing of the drug prevention and treatment cost of coccidiosis, the generation of drug-resistant insect strains, the influence of drug residues on the quality of the meat poultry and the human health and other problems, the feed conversion rate of the chicken flocks is also greatly reduced, the highly toxic coccidia vaccine has the defects of strong toxicity, short storage time, unchanged transportation and the like, the coccidia vaccine weakened by chemical agents has larger stress, therefore, the development of a physically or biologically attenuated live attenuated coccidian attenuated vaccine will become a research hotspot in the broiler breeding industry.
Disclosure of Invention
Aiming at the needs of the prior art, the invention aims to provide a chicken coccidiosis trivalent live vaccine which is prepared by reasonably mixing and storing three insect strains of attenuated by precocity breeding, Eimeria tenella, Eimeria necatrix and Eimeria maxima, and has the advantages of convenient use, low cost, weak toxicity, good immunogenicity, high safety, reduction of manpower, material resources and time cost and reduction of harm to a host.
In order to realize the purpose, the invention is realized by the following technical scheme:
a chicken coccidiosis trivalent live vaccine comprises: 600-1200 Eimeria tenella pieces per head part, 700-1500 Eimeria necatrix pieces per head part, and 200-800 Eimeria maxima per head part.
The chicken coccidiosis trivalent live vaccine comprises the following components: 900 Eimeria tenella pieces/head, 1200 Eimeria necatrix pieces/head, 300 Eimeria maxima pieces/head.
In the chicken coccidiosis trivalent live vaccine, the eimeria tenella, eimeria necatrix and eimeria maxima coccidian strains are precocious breeding attenuated insect strains.
The chicken coccidiosis trivalent live vaccine is applied, and the immunization mode of the live vaccine is spraying and stirring.
A preparation method of a chicken coccidiosis trivalent live vaccine comprises the following steps: the early breeding attenuated strains of three kinds of eimeria tenella, eimeria necatrix and eimeria maxima are mixed homogeneously and stored in preserving liquid.
The preservation solution in the preparation method of the chicken coccidiosis trivalent live vaccine comprises 1% -5% of chloramine T solution.
The invention has the advantages and beneficial effects that:
1. the invention aims to provide a preparation method and application of a chicken coccidiosis trivalent live vaccine.
2. The vaccine of the invention has good immunogenicity, no toxicity, no drug residue and no drug resistance, and has high safety.
3. After the immune of the invention, the chicken coccidiosis and enteritis infected by three insect strains of Eimeria tenella, Eimeria necatrix and Eimeria maxima can be prevented.
4. The invention fills the defects of chemical or dual attenuated coccidian strains in the prior art in the industry, and has the advantages of small stress and good anti-infection capability.
Detailed Description
The invention is further illustrated by the following examples. It should be noted that: the following examples are illustrative and not intended to be limiting, and are not intended to limit the scope of the invention.
Example 1
A preparation method and application of a chicken coccidiosis trivalent live vaccine are disclosed, wherein the preparation method comprises the following steps:
(1) the method comprises the steps of carrying out precocious breeding on three kinds of eimeria tenella, eimeria necatrix and eimeria maxima for 3-30 generations, and continuously evaluating the pathogenicity of each breeding insect strain until the requirements of the vaccine strain with low pathogenicity, high immunogenicity and high cross protection rate are met.
(2) Counting three kinds of coccidian sporulated oocysts of Eimeria tenella, Eimeria necatrix and Eimeria maxima by using a blood counting plate, calculating the required number of the coccidian oocysts according to 600 per head part of Eimeria tenella, 700 per head part of Eimeria necatrix and 200 per head part of Eimeria maxima, putting the coccidian oocysts into a clean container, adding a preservation solution containing 1% chloramine T solution, stirring to obtain a mixed insect strain oocyst solution with the corresponding component parts, and preserving in an environment at 2-8 ℃ for later use.
Example 2
A preparation method and application of a chicken coccidiosis trivalent live vaccine are disclosed, wherein the preparation method comprises the following steps:
(1) the method comprises the steps of carrying out precocious breeding on three kinds of eimeria tenella, eimeria necatrix and eimeria maxima for 3-30 generations, and continuously evaluating the pathogenicity of each breeding insect strain until the requirements of the vaccine strain with low pathogenicity, high immunogenicity and high cross protection rate are met.
(2) Counting three kinds of coccidian sporulated oocysts of Eimeria tenella, Eimeria necatrix and Eimeria maxima by using a blood counting plate, calculating the required number of the coccidian oocysts according to 1200 parts per head of Eimeria tenella, 1500 parts per head of Eimeria necatrix and 800 parts per head of Eimeria maxima, putting the coccidian oocysts into a clean container, adding a preservation solution containing 5% chloramine T solution, stirring to obtain a mixed insect strain oocyst solution with the corresponding component parts, and preserving in an environment at 2-8 ℃ for later use.
Example 3
A preparation method and application of a chicken coccidiosis trivalent live vaccine are disclosed, wherein the preparation method comprises the following steps:
(1) the method comprises the steps of carrying out precocious breeding on three kinds of eimeria tenella, eimeria necatrix and eimeria maxima for 3-30 generations, and continuously evaluating the pathogenicity of each breeding insect strain until the requirements of the vaccine strain with low pathogenicity, high immunogenicity and high cross protection rate are met.
(2) Counting three kinds of coccidian sporulated oocysts of Eimeria tenella, Eimeria necatrix and Eimeria maxima by using a blood counting plate, calculating the required number of the coccidian oocysts according to 900 Eimeria tenella per head part, 1200 Eimeria necatrix per head part and 300 Eimeria maxima per head part, putting the coccidian oocysts into a clean container, adding a preservation solution containing 2% chloramine T solution, stirring to obtain a mixed insect strain oocyst solution with the corresponding component parts, and storing in an environment at 2-8 ℃ for later use.
Clinical trial
1. Test protocol
(1) Sample size and grouping: 300 SPF (specific pathogen free) chickens of 1 day old are selected to be bred in an experimental animal room with a barrier facility, and are randomly divided into 6 groups, wherein each group comprises 50 SPF chickens, 1-3 groups are experimental groups of the invention, 4 groups are blank control groups, 5 groups are attack-immunization-free control groups, 6 groups are commercial anticoccidial drug treatment groups,
(2) vaccine use groups: group 1: prepared according to the method of example 1; and 2, group: prepared as in example 2; and 3, group: prepared according to the method of example 3;
(3) test procedure:
group 1: the vaccine prepared in example 1 was fed to 1 group at 9 days of age by means of spray dressing, a 25 day old insect challenge test, 4 ten thousand oocysts/feather, with a weight record per feather for 9 and 25 days.
And 2, group: the vaccine prepared in example 2 was fed to 2 groups at 9 days of age by means of spray dressing, a 25 day-old insect challenge test, 4 ten thousand oocysts/feather, with a weight record per feather for 9 and 25 days.
And 3, group: the vaccine prepared in example 3 was fed to 3 groups at 9 days of age by means of spray dressing, a 25 day-old insect challenge test, 4 ten thousand oocysts/feather, with a weight record per feather for 9 and 25 days.
4 groups are as follows: the animals were not attacked and immunized, and the feather weight was recorded only on 9 and 25 days.
And (5) weighing.
And 5, group: nonimmunity, at 25 days of age, 4 million oocysts/feather, and weight per feather recording at 9 and 25 days.
6 groups are as follows: nonimmunity, 4 ten thousand oocysts/feather in a 25-day-old challenge test, treatment with the same dose according to commercially available anticoccidial drug instructions, and weight-per-feather recording on 9 and 25 days.
The relative weight gain rate is the average weight gain rate of the test group/the average weight gain rate of the healthy control group multiplied by 100%.
2. Results
TABLE 1 comparison of the immunization effects of the trivalent live vaccine of coccidiosis in Chicken
Group of Sample size/plume Relative rate of increase in weight% Survival rate%
1 50 38.45 100
2 50 36.67 98
3 50 40.91 100
4 50 25.0 50
5 50 15 30
6 50 34.33 80
3. Small knot
By comparing the control conditions of the coccidiosis in the experimental groups and the control groups of chicken flocks with the relative weight gain rate and the survival rate in the table, the effect of the invention on preventing the coccidiosis in the chicken is obviously better than that of the chemical group and the control group, and in addition, the intestinal mucosa can be protected and the feed conversion rate can be improved.

Claims (6)

1. A preparation method and application of a chicken coccidiosis trivalent live vaccine are characterized by comprising the following steps: 600-1200 Eimeria tenella pieces per head part, 700-1500 Eimeria necatrix pieces per head part, and 200-800 Eimeria maxima per head part.
2. A trivalent live vaccine against coccidiosis in chicken according to claim 1, comprising: 900 Eimeria tenella pieces/head, 1200 Eimeria necatrix pieces/head, 300 Eimeria maxima pieces/head.
3. The trivalent live vaccine against chicken coccidiosis as set forth in claim 1, wherein the three coccidia strains of Eimeria tenella, Eimeria necatrix and Eimeria maxima are all precocious breeding attenuated insect strains.
4. The use of the trivalent live vaccine against chicken coccidiosis according to claim 1, wherein the live vaccine is administered by spraying and mixing.
5. A method for preparing trivalent live vaccine of chicken coccidiosis as described in any one of claims 1-4, which is prepared by mixing Eimeria tenella, Eimeria necatrix and Eimeria maxima, and preserving in a preserving solution.
6. The preservation solution for preparing the chicken coccidiosis trivalent live vaccine according to claim 5, which comprises a chloramine T solution with a concentration of 1% -5%.
CN201910941406.2A 2019-09-30 2019-09-30 Preparation method and application of chicken coccidiosis trivalent live vaccine Withdrawn CN110664997A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910941406.2A CN110664997A (en) 2019-09-30 2019-09-30 Preparation method and application of chicken coccidiosis trivalent live vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910941406.2A CN110664997A (en) 2019-09-30 2019-09-30 Preparation method and application of chicken coccidiosis trivalent live vaccine

Publications (1)

Publication Number Publication Date
CN110664997A true CN110664997A (en) 2020-01-10

Family

ID=69078791

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910941406.2A Withdrawn CN110664997A (en) 2019-09-30 2019-09-30 Preparation method and application of chicken coccidiosis trivalent live vaccine

Country Status (1)

Country Link
CN (1) CN110664997A (en)

Similar Documents

Publication Publication Date Title
Zhang et al. Investigation into the prevalence of coccidiosis and maduramycin drug resistance in chickens in China
Peek et al. Coccidiosis in poultry: anticoccidial products, vaccines and other prevention strategies
Hauck et al. Experimental infections with the protozoan parasite Histomonas meleagridis: a review
US20070148186A1 (en) Simarouba amara and/or momordica charantia extracts for the treatment of coccidiosis in poultry
Barbour et al. A review of approaches targeting the replacement of coccidiostat application in poultry production
CN109646674B (en) Coccidiosis live vaccine and application thereof
Guo et al. Coccidiosis immunization: effects of mushroom and herb polysaccharides on immune responses of chickens infected with Eimeria tenella
Richeson et al. Effects of administration of a modified-live virus respiratory vaccine and timing of vaccination on health and performance of high-risk beef stocker calves
CN107019111B (en) Composition for improving yield of oocysts of eimeria maxima and preparation method thereof
CN107022487B (en) Preparation method and application of coccidian oocyst activity protective agent in chicken manure
Lee et al. Evaluation of live oocyst vaccination or salinomycin for control of field-strain Eimeria challenge in broilers on two different feeding programs
CN110694058B (en) Rabbit coccidiosis live vaccine and preparation method and application thereof
Undiandeye et al. Immunostimulatory effect of levamisole on the immune response of goats to peste des petits ruminants (PPR) vaccination
CN110664997A (en) Preparation method and application of chicken coccidiosis trivalent live vaccine
CN102078598B (en) Injection for preventing and treating porcine viral diseases and preparation method thereof
CN108619498A (en) A kind of coccidiosis of rabbit vaccine and its application
CN107019799A (en) A kind of application of chicken coccidiasis tetravalence attenuated live vaccines composition in production
Long et al. Immunisation against coccidiosis in chickens: tests under simulated field conditions
Bafundo et al. The effects of a quillaja/yucca saponin combination on performance, Clostridium perfringens counts and percentage of Salmonella positive broiler chickens
McDougald et al. Susceptibility of broilers to coccidiosis following early coccidiostat withdrawal
Chen et al. Observation of the excretion pattern of a precocious line of Eimeria necatrix and the strengthening of immune homogeneity
Enany et al. Evaluation of Echinacea immunomodulatory effect on the immune response of broiler chickens
CN105663604A (en) Traditional Chinese medicinal composition for treating chicken coccidiosis and preparation method of traditional Chinese medicinal composition
Phuong et al. Prophylactic and therapeutic methods against histomoniasis in poultry.
Zia-ur-Rehman et al. Comparative therapeutic efficacy of ivermectin and piperazine citrate against Ascaridia galli in commercial and rural poultry

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20200110

WW01 Invention patent application withdrawn after publication